The reason

Drug discovery is not like the transistor or integrated circuits technology where huge foundries are required and the catch-up phase is big.

A certain starkness marks the entrance to Curadev Pharma Private Limited. Freshly painted, the walls are bare; the reception desk is unmanned. The company does mostly science and doesn’t need a front desk; not yet. Ask them about the emptiness and co-founders Arjun Surya and Manish Tandon look at the ceiling and wistfully discuss how the AstraZeneca headquarters in Sweden had the hanging molecular structure of Omeprazole, the multi-billion-dollar anti-ulcer drug, greet visitors. “Maybe, one day, when one of our molecules becomes successful, we’ll have its molecular structure (mural) hanging here,” they say, almost in unison.

On the outskirts of Noida in Uttar Pradesh, flanked by hosiery makers, Sector 83 is not the best place to do drug discovery, the riskiest venture in life sciences. But for Surya these externalities are trivial. On the contrary, he asks you to take a thought experiment: “Why would anybody fund drug discovery? It’s a stupid business model. I may have to make 600 molecules before I find one that clicks. One molecule costs one lakh to make.”

That’s pricey. So they funded it themselves. By selling their house. And when they were still on the brink in April 2015, Roche came calling with a deal that paid $25 million upfront and had another $530 million promised in milestone payments. One of those payments is expected this year. So is a new, potentially large, licensing opportunity as Curadev’s next molecule readies for big pharma.

Will it hit the jackpot again? No one, except Glenmark, which has a sizeable generics business as its mainstay, has done this before. “Science is a very tough taskmaster,” says Surya. “You can’t wing it because you’ve done or seen it before. It’s very humbling.”

And how it humbled

Medium-built and greying in his early fifties, Surya comes across as a mix of sincerity, caution, and a devil-may-care attitude, in equal parts. Somewhat contradictory, you’d think. His entrepreneurial venture defies logic no less. Coming from a background in contract research, he partnered with Tandon, who had experience in generics manufacturing. The two started a company that would discover new drugs. A gamble no one has pulled off. Not in India.

For Surya, this was what he had returned to India for in 1999, after spending 13 years in the US.

Back then, as he was making up his mind, Surya came across an interview of Parvinder Singh, the former managing director of Ranbaxy, on Doordarshan. Singh’s pitch to young professionals was: If you are interested in drug discovery, come to Ranbaxy.


Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?


Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750


Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750


Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500


Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120


Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50


Single Story

Instant access to this story for a year along with comment privileges.

$ 20



What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at detailing the error or queries.